Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of CHEK2 status on radiosurgical outcomes in breast cancer brain metastases.

Neurosurgical review·2026
Same author

Reirradiation treatment effects in the clinic (ReTEC) proposal - proof of concept based on spinal cord dose tolerance for reirradiation with stereotactic body radiotherapy.

Journal of applied clinical medical physics·2026
Same author

[<sup>18</sup>F]DASA-23 PET/MRI evaluation in newly-diagnosed and recurrent high-grade glioma.

Neuroradiology·2026
Same author

Hepatoblastoma brain metastasis treated with stereotactic radiosurgery: Illustrative case and literature search.

Surgical neurology international·2026
Same author

Surgical resection versus stereotactic radiosurgery for succinate dehydrogenase-related hereditary head and neck paragangliomas.

Journal of neuro-oncology·2026
Same author

Cancer-related movement disorders: A scoping review and diagnostic approach.

Neuro-oncology practice·2025

Related Experiment Video

Updated: Apr 18, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.7K

Treatment options for optic pathway gliomas.

Reena P Thomas1, Iris C Gibbs, Linda Wei Xu

  • 1Stanford University Hospital, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.

Current Treatment Options in Neurology
|January 27, 2015
PubMed
Summary

Optic pathway gliomas, often low-grade, require individualized treatment based on location and symptoms. Observation is favored for minimally symptomatic cases, especially in children with neurofibromatosis type 1 (NF1), with chemotherapy as a primary intervention for progression.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

101

Related Experiment Videos

Last Updated: Apr 18, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.7K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

101

Area of Science:

  • Neuro-oncology
  • Pediatric neurosurgery
  • Ophthalmology

Background:

  • Optic pathway gliomas (OPGs) are typically low-grade neoplasms with variable prognoses.
  • Optimal management strategies for OPGs remain debated, influenced by patient age, tumor location, and visual status.
  • Many pediatric OPGs are associated with neurofibromatosis type 1 (NF1).

Purpose of the Study:

  • To outline a treatment approach for optic pathway gliomas based on tumor location.
  • To provide guidance on managing OPGs, particularly in children with NF1.
  • To differentiate treatment strategies based on tumor histology and patient presentation.

Main Methods:

  • Treatment decisions guided by tumor location (anterior, chiasmal, posterior/hypothalamic visual pathways).
  • Emphasis on observation for minimally symptomatic pediatric patients, especially those with NF1.
  • Serial neuro-imaging and neuro-ophthalmology assessments for monitoring.
  • Chemotherapy as a preferred first-line treatment for progressive disease in NF1 patients.
  • Biopsy recommended for non-NF1 chiasmal/hypothalamic masses to determine histology.
  • Surgery considered for structural issues like proptosis after vision loss.

Main Results:

  • Observation is a viable strategy for asymptomatic or minimally symptomatic OPGs, particularly in NF1.
  • Chemotherapy is effective and recommended over radiation for progressive OPGs in NF1 children to protect CNS development.
  • Malignant OPGs require treatment similar to gliomas in other locations, involving radiation and chemotherapy.

Conclusions:

  • A location-dependent, individualized treatment approach is crucial for optic pathway gliomas.
  • Observation and chemotherapy are key components of managing OPGs in children, especially those with NF1.
  • Histology and clinical presentation dictate the need for biopsy, chemotherapy, radiation, or surgery.